Epristeride is a 5α-reductase inhibitor primarily utilized in the treatment of benign prostatic hyperplasia (BPH) by reducing dihydrotestosterone (DHT) levels. This category includes specialized reference… Read more
















Epristeride is a 5α-reductase inhibitor primarily utilized in the treatment of benign prostatic hyperplasia (BPH) by reducing dihydrotestosterone (DHT) levels. This category includes specialized reference standards for Epristeride, as well as its related impurities, metabolites, and stable isotope labelled compounds. These materials are essential for pharmaceutical laboratories performing rigorous analytical testing, method validation, and routine quality control of the drug substance. By providing a comprehensive range of accurately characterized materials, this collection supports precise impurity profiling and the development of sensitive detection methods. Scientists and researchers rely on these stable isotope labelled compounds and related standards to ensure the safety and efficacy of pharmaceutical formulations throughout the development cycle and regulatory compliance processes.